← All trials
NCT06714838
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2024
- Primary completion
- Oct 31, 2027
- Completion date
- Oct 31, 2028
- First posted
- Dec 4, 2024
- Last posted
- Dec 4, 2024
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AmsterdamLead sponsor
- Erasmus University RotterdamCollaborator
- Stichting TreatmedsCollaborator
- University of AmsterdamSponsor investigator
- Utrecht UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.